Table 3.
Comparison of different prevalence measures of SARS-CoV-2 antibodies (n = 2186).
| Prevalence measure | SARS-CoV-2 seroprevalence (unadjusted, n = 72), % (95% CI)] | SARS-CoV-2 seroprevalence (adjusteda, n = 72), % (95% CI) | Participants with neutralising antibodies titresb (n = 66), % (95% CI) |
|---|---|---|---|
| Overall seroprevalence | 3.3 (2.6–4.1) | 3.1 (2.4–4.0) | 3.0 (2.4–3.8) |
| Percentage of those who are seropositive and had a positive PCR before study | 2.1 (1.6–2.8) | 1.9 (1.4–2.6) | N/A |
| Percentage of those with neutralising antibody titres and a positive PCR before study | 45.5 (34.0–57.4) | 45.0 (34.1–57.6) | N/A |
CI, confidence interval; N/A, not applicable.
a
Adjusted for Roche Cobas Elecsys Anti-SARS-CoV-2 test sensitivity and specificity.
b
Only in case of a positive Roche Cobas Elecsys Anti-SARS-CoV-2 test (n = 66) neutralising antibody titre assay was performed.